Before Invest
ABBOTT LABORATORIES logo

ABBOTT LABORATORIES

ABT
Pharmaceutical Preparations
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Unlock 40 quarters
Statement
Period
Annual Quarterly
Order
Format
% Change
Rows
USD ($)
$ in Millions, shares in Thousands		Jun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024Mar 31, 2024Sep 30, 2023Jun 30, 2023Mar 31, 2023Sep 30, 2022Jun 30, 2022Mar 31, 2022Sep 30, 2021Jun 30, 2021Mar 31, 2021Sep 30, 2020Jun 30, 2020Mar 31, 2020Sep 30, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jun 30, 2018Mar 31, 2018Sep 30, 2017Jun 30, 2017Mar 31, 2017Sep 30, 2016Jun 30, 2016Mar 31, 2016Sep 30, 2015Jun 30, 2015Mar 31, 2015Sep 30, 2014Jun 30, 2014Mar 31, 2014Sep 30, 2013Jun 30, 2013Mar 31, 2013Sep 30, 2012Jun 30, 2012Mar 31, 2012Sep 30, 2011Jun 30, 2011Mar 31, 2011Sep 30, 2010Jun 30, 2010Mar 31, 2010Sep 30, 2009Jun 30, 2009
Net sales
$ 12,593
$ 11,164
$ 11,369
$ 11,142
$ 10,358
$ 10,635
$ 10,377
$ 9,964
$ 10,143
$ 9,978
$ 9,747
$ 10,410
Cost of products sold, excluding amortization of intangible assets
5,325
4,890
5,075
4,854
4,468
4,698
4,603
4,463
4,605
4,483
4,331
4,629
Amortization of intangible assets
658
422
420
420
420
470
471
472
496
498
491
498
Research and development
892
767
766
725
716
713
698
684
672
715
654
782
Acquired in-process and collaborations research and development
-
-
-
-
-
-
-
-
-
-
-
-
Acquired in-process research and development
-
-
-
-
-
-
-
-
-
-
-
-
Selling, general, and administrative
4,025
3,740
3,051
3,091
3,061
2,895
2,936
2,959
2,723
2,740
2,762
2,731
Total operating cost and expenses
10,900
9,819
9,312
9,090
8,665
8,776
8,708
8,578
8,496
8,436
8,238
8,640
Operating earnings
1,693
1,345
2,057
2,052
1,693
1,859
1,669
1,386
1,647
1,542
1,509
1,770
Interest expense
(351)
(174)
(121)
(121)
(131)
(142)
(140)
(141)
(166)
(159)
(153)
(141)
Interest (income)
52
106
77
71
82
91
82
80
97
98
101
55
Net foreign exchange (gain) loss
(4)
13
17
11
7
11
6
0
10
(21)
(6)
(19)
Net loss on extinguishment of debt
-
-
-
-
-
-
-
-
-
-
-
-
Other (income) expense, net
134
159
150
137
127
121
(10)
111
83
176
111
93
Earnings before taxes
1,524
1,449
2,180
2,150
1,778
1,940
1,607
1,436
1,671
1,636
1,562
1,758
Taxes on earnings
596
372
536
371
453
294
305
211
235
261
244
323
Earnings from continuing operations
-
-
-
-
-
-
-
-
-
-
-
-
Earnings (loss) from discontinued operations, net of tax
-
-
-
-
-
-
-
-
-
-
-
-
Gain on sale of discontinued operations, net of tax
-
-
-
-
-
-
-
-
-
-
-
-
Earnings from discontinued operations, net of tax
-
-
-
-
-
-
-
-
-
-
-
-
Earnings from discontinued operations, net of tax
-
-
-
-
-
-
-
-
-
-
-
-
Net Earnings
$ 928
$ 1,077
$ 1,644
$ 1,779
$ 1,325
$ 1,646
$ 1,302
$ 1,225
$ 1,436
$ 1,375
$ 1,318
$ 1,435
Basic Earnings Per Common Share --
                                                    
Continuing operations
-
-
-
-
-
-
-
-
-
-
-
-
Discontinued operations (in dollars per share)
-
-
-
-
-
-
-
-
-
-
-
-
Basic Earnings Per Common Share (in dollars per share)
0.53
0.62
0.94
1.02
0.76
0.94
0.74
0.7
0.82
0.79
0.75
0.82
Diluted Earnings Per Common Share --
                                                    
Continuing operations
-
-
-
-
-
-
-
-
-
-
-
-
Discontinued operations (in dollars per share)
-
-
-
-
-
-
-
-
-
-
-
-
Diluted Earnings Per Common Share (in dollars per share)
0.53
0.61
0.94
1.01
0.76
0.94
0.74
0.7
0.82
0.78
0.75
0.81
Cash Dividends Declared Per Common Share (in dollars per share)
-
-
-
-
-
-
-
-
-
-
-
-
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)
1,740,420
1,742,480
1,742,142
1,743,437
1,739,206
1,739,466
1,743,040
1,740,203
1,738,700
1,740,359
1,741,738
1,752,968
Dilutive Common Stock Options (in shares)
2,561
4,593
7,219
7,398
8,014
8,131
8,113
9,449
9,589
9,889
9,977
10,685
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)
1,742,981
1,747,073
1,749,361
1,750,835
1,747,220
1,747,597
1,751,153
1,749,652
1,748,289
1,750,248
1,751,715
1,763,653
Outstanding Common Stock Options Having No Dilutive Effect (in shares)
11,873
9,900
1,443
1,442
1,431
6,905
8,855
6,892
7,334
5,474
7,332
5,445